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Abstract: The mortality and incidence of chronic obstructive pulmonary disease (COPD) and 
coronary heart disease increase with age. Despite the clear evidence of beta blockers (BBs) 
effectiveness, there is a general reluctance to use them in patients with COPD due to a per-
ceived contraindication and fear of inducing adverse reactions and bronchspasm. BBs are well 
tolerated in patients with cardiac disease and concomitant COPD with no evidence of worsen-
ing of respiratory symptoms or FEV1, and the safety of BBs in patients with COPD has been 
demonstrated, but their use in this group of patients remains low. The cumulative evidence from 
trials and meta-analysis indicates that cardioselective BBs should not be withheld in patients 
with reactive airway disease or COPD.
Patients with COPD have a high incidence of cardiac events necessitating careful consider-
ation of prophylactic treatment. The beneﬁ  ts of beta blockade in this group appear to outweigh 
any potential risk of side effects according to the available evidence.
In this article, we will discuss the use of BBs in patients with COPD and review the evidence 
for their use and safety in this group of patients.
Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death 
and is estimated to rise to be the third most common cause of death worldwide by 2020 
(Rielly et al 2005). Many patients with COPD have concomitant conditions, mostly 
coronary artery disease (CAD), that require the use of beta-blockers (BBs). However, 
despite the clear evidence of BBs effectiveness, there is a general reluctance to use 
them in patients with COPD due to a perceived contraindication and fear of inducing 
adverse reactions and bronchspasm (Kennedy and Rosenson 1995; Viskin and Barron 
1996; Gottlieb et al 1998; Chaﬁ  n et al 1999). It is a common practice of physicians to 
consider COPD as contraindication to the use of BBs, based mainly on anecdotal evi-
dence and case reports citing acute bronchospasm following the administration of BBs 
(Tattersﬁ  eld 1986, 1990; Belli and Topol 1995; Craig et al 1996; Kendall 1997).
The most common comorbid conditions associated with withholding BBs in elderly 
patients after myocardial infarction (MI) are COPD and asthma (Heller et al 2000), 
while peripheral arterial and bronchial problems are reported to be the leading side 
effects (Frishman et al 1979; Frishman 1998). On the other hand, many patients are 
diagnosed and treated for COPD with no objective evidence, such as pulmonary func-
tion tests or specialist assessment, to conﬁ  rm the diagnosis, as recommended by most 
thoracic societies. This may indicate that a signiﬁ  cant number of patient are deprived 
the prognostic beneﬁ  ts of using BBs (Chen et al 2001).
BBs are well tolerated in patients with cardiac disease and concomitant COPD with 
no evidence of worsening of respiratory symptoms or FEV1 (Formgren 1976; George 
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et al 1983; Quan et al 1983; Krauss et al 1984; Falliers et al 
1985; Dorrow, Bethge et al 1986; Mooss et al 1994) and the 
safety of BBs in patients with COPD has been demonstrated, 
but their use in this group of patients remains low (Salpeter 
et al 2001, 2002a, 2002b, 2003). The cumulative evidence 
from trials and meta-analysis indicates that cardioselective 
BBs should not be withheld in patients with reactive airway 
disease or COPD (Salpeter et al 2001, 2002a, 2002b, 2003). 
Patients with COPD have a high incidence of cardiac events 
necessitating careful consideration of prophylactic treatment. 
The beneﬁ  ts of beta blockade in this group appear to outweigh 
any potential risk of side effects according to the available 
evidence. For instance, BBs are well tolerated by the large 
majority of patients with heart failure, even in those with 
comorbid conditions such as diabetes mellitus, COPD, and 
peripheral vascular disease (HFSA 2006).
In this article, we will discuss the use of BBs in patients 
with COPD and review the evidence for their use and safety 
in this group of patients.
Beta-blockers
Beta-blockers were originally designed by the Nobel 
Prize winner Sir James Black to counteract the adverse 
effects of adrenergic stimulation. He demonstrated that, by 
blocking the cardiac ß-receptors, these agents could cause 
inhibitory effects on the sinus node (chronotropic effect), 
atrioventricular node (dromotropic effect), and on myocardial 
contractility (inotropic effect).
There are 3 types of β receptors. β1-Adrenoceptors are 
situated in the cardiac sarcolemma. If activated, they lead to 
an increase in the rate and force of myocardial contraction 
(positive inotropic effect) by opening the calcium channels. 
On the other hand, β2-Adrenoceptors are found mainly in 
bronchial and vascular smooth muscles. If activated, they 
cause broncho- and vaso-dilatation. There are, however, 
sizable populations of β2-Adrenoceptors in the myocardium, 
of about 20%–25%, which leads to the cardiac effects 
of any β2-Adrenoceptors stimulation. There is a relative 
up-regulation of these receptors to about 50% in heart failure. 
The role of β3-Adrenoceptors in the heart is not yet fully 
identiﬁ  ed and accepted (Kalinowski et al 2003).
Beta-blockers are classified into three generations 
(Figure 1). The ﬁ  rst generation agents (such as Proprano-
lol, Sotalol, Timolol, and Nadolol), are nonselective and 
block β1 and β2 receptors. Blocking β1-receptors affects 
the heart rate, conduction and contractility, while blocking 
β2-receptors, tends to cause smooth muscle contraction, 
therefore, bronchospasm in predisposed individuals. The 
second-generation agents or the cardioselective agents 
(such as Atenolol, Bisoprolol, Celiprolol, and Metoprolol) 
block β1-receptors in low doses but are capable of blocking 
β2-receptors in higher doses. This selective mode of action 
makes the use of these agents more suitable in patients with 
chronic lung disease (Wellstien et al 1987) or those with 
insulin-requiring diabetes mellitus. Cardioselectivity varies 
between agents with the Bisoprolol among the most selective. 
The third generation agents have vasodilatory properties. 
There action is either selective (Nebivolol) or nonselective 
(Carvidolol and Labetolol). The vasodilatory properties 
are mediated either by nitric oxide release as for Nebivolol 
or Carvidolol (Kalinowski et al 2003) or by added alpha-
adrenergic blockade as in Labetolol and Carvidolol. A third 
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Figure 1 Beta blockers classiﬁ  cation.
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vasodilatory mechanism, as in Pindolol and Acebutolol, acts 
via β2-intrinsic sympathomimetic activity (ISA). These beta-
blockers therefore have the capacity to stimulate as well as to 
block adrenergic receptors and tend to cause less bradycardia 
than the other beta-blockers and may cause less coldness of 
the extremities.
Beta-blockers are used extensively and have a proven 
morbidity and mortality beneﬁ  ts in the management of 
patients with cardiac disease (Frishman 1984; The IPPPSH 
Collaborative Group 1985; Wadworth et al 1991; Stienbeck 
et al 1992; Mangano et al 1996; Doughty et al 1997; JNC VI 
1997; Lechat et al 1998; Freemantle et al 1999; Heidenreich 
et al 1999; Poldermans et al 1999). They are a standard 
therapy for hypertension, angina, unstable angina, post 
myocardial infarction, tachyarrhythmias, and congestive 
heart failure (The MERIT-HF Study Group 2000; Packer 
et al 2001). BBs also reduce mortality in the perioperative 
period. Despite the evidence, their use remains low in patients 
with COPD.
Beta-blockers use in COPD
Many patients with COPD have concomitant conditions 
such as CAD (coexists in up to 27% of COPD patients 
(Karoli and Rebrov 2005)) that require the use of BBs. BBs 
are often avoided in these patients (Kennedy and Rosenson 
1995; Viskin and Barron 1996; Gottlieb et al 1998; Chaﬁ  n 
et al 1999) because of fear of bronchospasm and possible 
adverse reactions, despite the known cardiovascular mortal-
ity and morbidity beneﬁ  t (Frishman et al 1984; The IPPPSH 
Collaborative Group 1985; Wadworth et al 1991; Stienbeck 
et al 1992; Mangono et al 1996; Doughty et al 1997, JNC VI 
1997; Lechat et al 1998; Freemantle et al 1999; Heidenreich 
et al 1999; Polderman et al 1999). This is mainly based 
on anecdotal evidence and case reports citing acute bron-
chospasm following the administration of beta-blocker 
(Tattersﬁ  eld 1986, 1990; O’Malley et al 1991; Belli and 
Topol 1995; Craig et al 1996; Kendall 1997).
COPD patients are at greater risk of ischaemic heart 
disease than asthmatics, so would beneﬁ  t from the use of 
BBs. On the other hand, they also have more severe airway 
obstruction, so may be more sensitive to small changes in 
FEV1 due to beta-blockade.
The trial evidence
The use and effectiveness of BBs therapy after MI for elderly 
patients with COPD or asthma was evaluated (Chen et al 
2001).The study was rationalised by the fact that patients with 
COPD and asthma have largely been excluded from clinical 
trials of BBs therapy for AMI. The authors used the data 
from the Cooperative Cardiovascular Project (Marciniak et al 
1998) to examine the relationship between discharge use of 
BBs and one-year mortality in patients with COPD or asthma 
who were divided into three groups: those who are not using 
beta-agonists, those who are using beta-agonists, and those 
with severe disease (on prednisone or previous hospitaliza-
tion) in comparison with patients free from COPD or asthma. 
Of 54,962 patients without contraindications to beta-blockers, 
patients with COPD or asthma (20%) were signiﬁ  cantly less 
likely to be prescribed beta-blockers at discharge after AMI. 
Patients with COPD or asthma who were not on beta-agonist 
had lower one-year mortality if they were on BBs. This 
mortality beneﬁ  t was not found among patients using beta-
agonists or those with severe COPD or asthma.
Large meta-analyses were published by Salpeter et al 
(2001, 2002a, 2002b) where randomized, blinded, placebo-
controlled trials that studied the effects of cardioselective BBs 
on FEV1, symptoms, and the use of inhaled β2-agonists in 
patients with reactive airway disease were selected, of which, 
there were 19 single dose treatment studies and 10 continued 
treatment studies. The outcomes measures were the change 
in FEV1 from baseline, the number of patients with respira-
tory symptoms, and the use of inhaled β2-agonists with 
active treatment compared with placebo. The results were 
that no signiﬁ  cant treatment effect in terms of FEV1 was 
found in patients with concomitant COPD, whether single 
doses (change in FEV1, –5.28% [CI, –10.03% to –0.54%]) or 
continued treatment (change in FEV1, 1.07% [CI, –3.3% to 
5.44%]) was used. The conclusion was that cardioselective 
BBs do not produce clinically signiﬁ  cant adverse respiratory 
effects in patients with mild to moderate reactive airway dis-
ease, and that they should not be withheld from these patients. 
The studies were not designed to make recommendations 
about people with signiﬁ  cant chronic airway obstruction.
A similar review on a similar cohort of patients 11 single 
dose treatment studies (Schanning and Vilsvik 1976; Beil and 
Ulmer 1977; McGavin and Williams 1978; Perks et al 1978; 
Sinclair 1979; Anderson et al 1980; Sorbini et al 1982; Von 
Wichert 1982; Adam et al 1984; Dorow, Bethge et al 1986; 
Macquin-Mavier et al 1988) and 8 continued treatment stud-
ies (Tivenius 1976; Wunderlich et al 1980; Ranchod et al 
1982; Buttand et al 1983; Fenster et al 1983; Lammers et al 
1985; Dorow, Clauzel et al 1986; Fogari et al 1990) was also 
published by the previous group (Salpeter et al 2003). This 
demonstrated that cardioselective BBs produced no signiﬁ  cant 
change in FEV1 or respiratory symptoms compared to placebo 
and did not signiﬁ  cantly affect the FEV1 treatment response to International Journal of COPD 2007:2(4) 538
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β2-agonists. Subgroup analysis revealed no signiﬁ  cant change 
in results for those participants with severe COPD or for those 
with a reversible obstructive component. The conclusion was 
again that cardioselective BBs given to COPD patients do 
not produce a signiﬁ  cant reduction in airway function or an 
increase in the incidence of COPD exacerbations.
A retrospective study (Egred et al 2005) assessed the 
use of BBs in patients with COPD admitted with acute 
coronary syndrome (ACS). Only 54% were discharged on 
BBs. A diagnosis of “COPD” was the most common cause 
for withholding BBs and only 62% of patients with COPD 
have been reviewed by a chest physician or had a previous 
pulmonary function test. Of these COPD patients, only 16% 
were prescribed BBs and many patients with a diagnosis of 
COPD have no objective evidence to support this diagnosis. 
The conclusion was that, these patients are being denied the 
prognostic beneﬁ  ts of BBs when presenting with ACS, and 
the recommendation was that before withholding BBs, COPD 
and reversibility should be ascertained by pulmonary func-
tion testing and that the overall use of BBs was sub-optimal 
in this setting.
The use of BBs in congestive heart failure patients with 
COPD and/or asthma was also assessed in a retrospective 
analysis (Peters et al 2004). One thousand sixty seven patients 
with CHF were included and reviewed over 18 months 
period. Medications, non-routine ofﬁ  ce visits, emergency 
room visits, and hospitalizations for respiratory events were 
assessed. Of the 1067 patients, 19.6% had obstructive pulmo-
nary disease (OLD): 5.9% asthma, 11.2% COPD and 2.5% 
asthma/COPD. Only 35.9% of the patients with OLD were 
on BBs half of which were cardioselective. The use of BBs 
did not result in any increased respiratory events, respira-
tory encounters, emergency room visits, or hospitalizations. 
The result showed that the long-term use of BBs did not 
increase the risk of respiratory complications and there was 
no difference in outcomes with the use of cardioselective or 
noncardioselective BBs and the conclusion was that cardio-
selective BBs without intrinsic sympathomimetic activity are 
preferred until future studies resolve this issue.
Most of the evidence presented is meta-analysis; there-
fore, it has many limitations like any other meta-analysis 
(Ionnidis and Lau 1999). It only reports on published litera-
ture and is therefore subject to publication bias. A few stud-
ies did not have placebo controls, and many did not provide 
standard deviations for FEV1 treatment effects. In addition, 
most of the studies were of short duration. It is possible that 
a longer study period may be required in order to detect 
clinically important side effects of BBs.
In the recent publication of the Heart Failure Society of 
America (HFSA) on heart failure practice guidelines (HFSA 
2006), BBs therapy is recommended in the great majority of 
patients with LV systolic dysfunction, even in the presence of 
concomitant COPD. They recommend that BBs are initiated 
at a low dose and uptitrated gradually in two weeks intervals. 
The guidelines also recommend that patients with difﬁ  culties 
in initiating, uptitrating, or maintaining BBs therapy to be 
referred to a physician with expertise in the management of 
these patients. This is to ensure that no patient is denied the 
beneﬁ  ts of BBs (HFSA 2006).
In this article, we presented a review of the data support-
ing the use of cardioselective BBs in patients with mild to 
moderate COPD. The evidence suggests that cardio-selective 
BBs are not only safe but also beneﬁ  cial in patients with 
co-existing airways and coronary disease and can sig-
niﬁ  cantly improve prognosis. Due to the proven mortality 
beneﬁ  t of BBs in numerous cardiac conditions, many of 
the other relative or absolute contraindications traditionally 
listed for BBs have been questioned, including impaired left 
ventricular function, peripheral vascular disease, and diabetes 
mellitus (Kjekshus et al 1990; Wichkmayr et al 1990; Radack 
and Deck 1991; Rosenson 1993; Jonas et al 1996; Gottlieb 
et al 1998; Lechat et al 1998).
Finally, although we believe physicians should feel 
more comfortable prescribing cardioselective BBs to COPD 
patients, we can not make a generalised recommendation that 
BBs can be used in all COPD patients. This is due to the fact 
that almost all of the evidence is from retrospective analysis 
of data available and more prospective studies are needed. 
Physicians should use their clinical judgment and use BBs 
where they think the beneﬁ  ts outweigh the risks.
We suggest that patients who are admitted with any 
cardiac condition requiring BBs and who have concomitant 
COPD should be tried on BBs. A safe approach is to initi-
ate cardio-selective BBs at a low dose and titrate them up 
as tolerated during the hospital admission. Metoprolol is 
cardioselective BBs with short half-life and has been shown 
to be safe and effective in patients with COPD (Camsari et al 
2003) and may be the BBs of choice to initiating therapy. This 
will allow close observation and assessment of tolerance of 
these medications and will ensure that these patients are not 
denied the prognostic beneﬁ  ts of a well-tolerated and effec-
tive treatment. It may be necessary to discontinue the drug 
in few patients due to bronchconstriction, but the potential 
beneﬁ  t appears large enough to warrant this small risk.
Further randomised studies may be required to assess the 
use of the new BBs (Nebivolol) with its nitric oxide (NO) International Journal of COPD 2007:2(4) 539
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releasing property in patient with COPD. This will allow 
the assessment of weather it is safe and similarly will help 
deﬁ  ne weather NO has any role to play in reducing the effect 
of BBs on bronchospasm.
A drug called Pimobendan which is a phosphodiesterase 
(PDE) III-inhibitor, with vasodilatory and bronchodilatory 
effects, has been used in two patients with heart failure who 
were unable to tolerate BBs. The use of Pimobendan allowed 
the start and maintenance of BBs without worsening COPD 
or heart failure with evidence of progressive decline in brain 
natriuretic peptide (BNP) (Shiga et al 2002). This may pres-
ent an interesting way of dealing with BBs intolerant patients, 
where the bronchdilatory effects of Pimobendan would 
allow the initiation of BBs. This is only two case reports 
and the safety and efﬁ  cacy of this drug has not been tested 
in a controlled manner.
Conclusion
BBs reduce mortality in patients with COPD and coexisting 
CAD and should be used whenever possible. Cardioselective 
BBs are safe in patients with COPD who have an indication 
for their use. Nonselective BBs are better avoided in general, 
except in patients with heart failure who may beneﬁ  t from the 
use of Carvedilol. A short acting cardioselective BBs (such 
as metoprolol) should be started at a low dose and uptitrated 
slowly. Once Metoprolol is established, it can be changed 
to a once daily longer acting product such as Bisoprolol 
or Atenolol. In case of uncertainty or difﬁ  culty, specialist 
opinion should be sought to insure that these patients are not 
denied the prognostic beneﬁ  t of BBs therapy.
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